Taiho Pharmaceutical Co., Ltd.

Clinical trials sponsored by Taiho Pharmaceutical Co., Ltd., explained in plain language.

Now part of Otsuka Holdings Co., Ltd. 4578 TOKYO

Japanese pharmaceutical company focused on oncology and other therapeutic areas.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New combo targets Hard-to-Treat stomach tumors Results expected Dec 2026 (estimated)
Can a new immunotherapy combo shrink Hard-to-Treat tumors? Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 4 Not yet finished but already full! 1 Completed 1

New combo targets Hard-to-Treat stomach tumors

Disease control Ongoing

This early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see…

Phase 1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:12 UTC

Taiho Pharmaceutical Co., Ltd.

Upcoming readouts

New combo targets Hard-to-Treat stomach tumors